http://www.stockton-press.co.uk/bip

## SPECIAL REPORT

## $Ser^{203}$ as well as $Ser^{204}$ and $Ser^{207}$ in fifth transmembrane domain of the human $\beta_2$ -adrenoceptor contributes to agonist binding and receptor activation

## <sup>1</sup>Takayuki Sato, <sup>1,2</sup>Hiroyuki Kobayashi, <sup>1</sup>Taku Nagao & \*,<sup>1</sup>Hitoshi Kurose

<sup>1</sup>Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan and <sup>2</sup>Drug Discovery Research Laboratory, 2-2-50 Kawagishi, Toda-shi, Saitama 335-8505, Japan

We examined the contribution of  $Ser^{203}$  of the human  $\beta_2$ -adrenoceptor ( $\beta_2$ -AR) to the interaction with isoprenaline. The affinity of (—)-isoprenaline was reduced by substitution of an alanine for  $Ser^{203}$ , as well as for  $Ser^{204}$  and  $Ser^{207}$ . An (—)-isoprenaline derivative with only one hydroxyl group, at the *meta*-position, showed reduced affinity for wild-type  $\beta_2$ -AR and  $Ser^{207}$ -AR and even lower affinities for  $Ser^{203}$ -AR and  $Ser^{204}$ -AR. By contrast, an (—)-isoprenaline derivative with only a *para*-hydroxyl group showed reduced affinity for wild-type  $\beta_2$ -AR but the serine to alanine mutations did not cause further decreases. The  $EC_{50}$  value for cyclic AMP generation in response to (—)-isoprenaline was increased, by about 120 fold, for each alanine-substituted  $\beta_2$ -AR mutant. These results suggest that  $Ser^{203}$  of the human  $\beta_2$ -AR is important for both ligand binding and receptor activation.

**Keywords:**  $\beta_2$ -adrenoceptor; catechol hydroxyl group; (-)-isoprenaline; serine residue; Ser<sup>203</sup>

Abbreviation: AR, adrenoceptor

**Introduction** The agonist and antagonist binding domains of the human  $\beta_2$ -adrenoceptor ( $\beta_2$ -AR) are thought to reside within the transmembrane domains (Dixon et al., 1987). It has been suggested that the protonated amines of  $\beta_2$ -AR agonists and antagonists interact with Asp<sup>113</sup> in the third transmembrane domain of the receptor (Strader et al., 1987). Strader et al. (1989) reported that Ser<sup>204</sup> and Ser<sup>207</sup> in the fifth transmembrane domain of  $\beta_2$ -AR serve as hydrogen bond donors or acceptors in the interaction with the catechol moiety of each agonist. They proposed that the meta- and parahydroxyl groups of (-)-isoprenaline interact with Ser<sup>204</sup> and Ser<sup>207</sup>, respectively. However, there is another serine (Ser<sup>203</sup>) in the fifth transmembrane domain. Strader et al. (1989) did not detect the expression in transfected cells of a  $\beta_2$ -AR mutant in which Ser<sup>203</sup> was replaced by an alanine, so they suggested that Ser<sup>203</sup> is necessary for proper folding of  $\beta_2$ -AR.

All catecholamine receptors contain two or three serines in the fifth transmembrane domain (Figure 1). It is thought that each of the hydroxyl groups of a catecholamine interacts with one of the receptor's serines in a manner similar to the interaction between Ser<sup>204</sup> and Ser<sup>207</sup> of human  $\beta_2$ -AR and isoprenaline. However, rat  $\alpha_{1A}$ -AR lacks a serine at the position homologous to Ser<sup>204</sup> of human  $\beta_2$ -AR. Hwa & Perez (1996) reported that Ser<sup>188</sup> of rat  $\alpha_{1A}$ -AR is homologous to Ser<sup>203</sup> of human  $\beta_2$ -AR and that it interacts with the *meta*hydroxyl group of adrenaline. The hamster  $\alpha_{1B}$ -AR has three serines (Ser<sup>207</sup>, Ser<sup>208</sup> and Ser<sup>211</sup>) and Cavalli et al. (1996) reported that a substitution mutation of Ser<sup>207</sup>, which is homologous to Ser<sup>203</sup> of human  $\beta_2$ -AR, decreases the affinity of agonists; they suggested that both Ser<sup>207</sup> and Ser<sup>208</sup> of hamster  $\alpha_{1B}$ -AR interact with the hydroxyl group in the *meta*-position. The human D<sub>1</sub> dopamine receptor also has three serines, which are homologous to Ser<sup>203</sup>, Ser<sup>204</sup> and Ser<sup>207</sup> of human  $\beta_2$ -AR, Here, we report the successful *in vitro* expression of a human  $\beta_2$ -AR mutant in which Ser<sup>203</sup> was replaced by an alanine. We examined the interactions of this mutant with (—)-isoprenaline and its derivatives.

**Methods** The plasmid pBC- $\beta_2$ , which encodes for the human  $\beta_2$ -AR, was kindly provided by Dr R.J. Lefkowitz of Duke University (NC, U.S.A.). The plasmid pEF-BOS was provided by Dr S. Nagata of Osaka University (Osaka, Japan) (Mizushima & Nagata 1990). (—)-Isoprenaline derivatives

rat	$\alpha_{\text{1A}}$	183	GYVLF	SALGS	FY	194
hamster	$\alpha_{\scriptscriptstyle 1B}$	202	FYALF	SSLGS	FY	213
human				SCIGS		
human	$\beta_2$	198	AYAIA	SS IVS 203204 IVS	FY	209
human	$D_1$	193	TYAIS	SSVIS	FY	204
rat	$D_2$	188	AFVVY	SSIVS	FY	199

Figure 1 Alignment of the fifth transmembrane domains of various catecholamine receptors.

and each one is critical for ligand binding and receptor activation (Pollock *et al.*, 1992). Similarly, the rat  $D_2$  dopamine receptor has three serines (Ser<sup>193</sup>, Ser<sup>194</sup> and Ser<sup>197</sup>) which are homologous to the serines of human  $\beta_2$ -AR, and all three are necessary for a maximal cyclic AMP response to a partial agonist (Cox *et al.*, 1992). Together, these findings indicate that the serines of various catecholamine receptors that are homologous to Ser<sup>203</sup> of human  $\beta_2$ -AR play important roles in ligand binding and receptor activation.

<sup>\*</sup>Author for correspondence; kurose@mol.f.u-tokyo.ac.jp

**Table 1** Binding characteristics of the wild type, S203A-, S204A- and S207A- $\beta_2$ -adrenoceptors

	$[^{125}I]$ -C	YP	$K_i (\mu M)$			
	$B_{max} \text{ (pmol mg}^{-1}\text{)}$	$K_{\mathrm{D}}$ (pm)	(-)-isoprenaline	meta-hydroxyl ISO	para-hydroxyl ISO	
wild type	$4.58 \pm 0.42$	$24.4 \pm 4.1$	$0.21 \pm 0.05$	$2.2 \pm 0.5*$	$3.4 \pm 0.2*$	
S203A-	$1.17 \pm 0.07 \dagger$	$46.1 \pm 10.8$	$2.9 \pm 0.7$	$8.3 \pm 1.3*$ †	$2.4 \pm 0.1$	
S204A-	$2.89 \pm 0.34 \dagger$	$17.9 \pm 0.8$	$6.9 \pm 0.3$	$14.8 \pm 1.6 * \dagger$	$5.6 \pm 1.1$	
S207A-	$2.62 \pm 0.11 \dagger$	$20.2 \pm 1.2$	$2.3 \pm 0.5$	$1.4 \pm 0.3$	$2.5 \pm 0.6$	

The wild-type and alanine-substituted mutants were expressed in COS-7 cells, and binding characteristics were determined. The dissociation constant  $(K_D)$  and maximal binding activity  $(B_{max})$  of  $[^{125}I]$ -iodocyanopindolol  $([^{125}I]$ -CYP) and  $K_i$  values of (-)-isoprenaline and its derivatives with one hydroxyl group at *meta*- (meta-hydroxyl ISO) or *para*-positions (para-hydroxyl ISO) were calculated with the Prism software package. The data are shown as means  $\pm$  s.e.mean from 3-4 separate experiments. Statistical significance was assessed by Dunnett's test: \*<0.01, different from (-)-isoprenaline;  $\dagger$ <0.01, different from the wild-type  $\beta_2$ -adrenoceptor.

were synthesized at the Drug Discovery Research Laboratory by Tanabe Seiyaku (Saitama, Japan). [125I]iodocyanopindolol ([125I]CYP) (2200 Ci mmol<sup>-1</sup>), [3H]-adenine (24.0–27.0 Ci mmol<sup>-1</sup>) and [14C]-cAMP (20.0–50.1 mCi mmol<sup>-1</sup>) were purchased from DuPont-New England Nuclear Research (Boston, MA, U.S.A.). Lipofectamine and cell culture reagents were from Life Technologies, Inc. (Rockville, MD, U.S.A.).


The construct of the  $\beta_2$ -AR mutants with alanine substitutions for Ser<sup>204</sup> or Ser<sup>207</sup>, S204A- $\beta_2$ -AR and S207A- $\beta_2$ AR, has been described elsewhere (Kikkawa *et al.*, 1997a). Alanine substitution of Ser<sup>203</sup> was made by Quick change method according to manufacturer's instruction (Stratagene, La Jolla, CA, U.S.A.). S203A- $\beta_2$ -AR was inserted into pEF-BOS due to low expression when the pCMV5 vector was used.

The transfection procedure, membrane preparation, receptor binding assays, and cyclic AMP accumulation assays were performed as described previously (Kikkawa *et al.*, 1997b).

The results are expressed as the mean  $\pm$  s.e.mean for n determinations. Statistical significance was assessed by ANOVA for multiple comparisons. ANOVA post hoc comparisons were made using Dunnett's test.

**Results** First, we determined the maximal binding activity  $(B_{max})$  and dissociation constant  $(K_D)$  for the wild-type and mutated  $\beta_2$ -ARs (Table 1). The expression levels of the mutants in transfected cells were significantly lower than that of the wild-type receptor, but were much higher than that of endogenous  $\beta$ -AR in COS-7 cells ( $\sim 10$  fmol mg<sup>-1</sup>) and were sufficient to study the binding characteristics of the mutants. As the  $K_D$  values of the mutants for [ $^{125}$ I]-CYP were not significantly different from that of the wild-type receptor, we concluded that the substitution of alanine for Ser $^{203}$ , Ser $^{204}$  or Ser $^{207}$  did not cause a global change in the  $\beta_2$ -AR structure.

The affinity of ( – )-isoprenaline for  $\beta_2$ -AR was reduced 10 – 30 fold by the serine to alanine substitutions: by about 30 fold for S204A- $\beta_2$ -AR, by about 10 fold for S207A- $\beta_2$ -AR and by about 10 fold for S203A- $\beta_2$ -AR. To examine the role of each hydroxyl group on the phenyl ring of the ligand in the interactions with the serine residues, (-)-isoprenaline derivatives were synthesized in which the meta- or para-hydroxyl group was changed to hydrogen. The affinities of these two derivatives for the wild-type receptor were about 10 fold lower than that of (-)-isoprenaline (Table 1). However, they showed at most 6 fold lower affinities for the alanine-substituted mutants than for the wild-type receptor. The affinity of the derivative with one hydroxyl group at the meta-position (metahydroxyl ISO in Table 1) for S203A- $\beta_2$ -AR and S204A- $\beta_2$ -AR, but not S207A- $\beta_2$ -AR was significantly reduced compared to the wild-type receptor. By contrast, the affinity of the derivative with one hydroxyl group at the para-position



**Figure 2** Effect of mutations of  $Ser^{203}$ ,  $Ser^{204}$  or  $Ser^{207}$  of human  $β_2$ -AR on isoprenaline-stimulated cyclic AMP generation. The CHO cells were transfected with the wild-type, S203A-, S204A- or S207A- $β_2$ -ARs, labelled with [ $^3$ H]-adenine, and stimulated with the indicated concentration of (-) - isoprenaline for 10 min in the presence of 1 mM isobutyl-1-methylxanthine. The EC<sub>50</sub> values were calculated with the Prism software package. To compare EC<sub>50</sub> values between the mutants, the maximal cyclic AMP generation of each experiment was set as 100%, and the other values were normalized to this value.

(*para*-hydroxyl ISO in Table 1) was not significantly affected by the substitution of alanine for Ser<sup>203</sup>, Ser<sup>204</sup> or Ser<sup>207</sup>.

To examine the functional role of the serine residue at position 203 in the activation of  $\beta_2$ -AR by (—)-isoprenaline, agonist-stimulated cyclic AMP generation was determined in CHO cells. Stimulation of each receptor with (—)-isoprenaline increased the intracellular cyclic AMP content (Figure 2). The EC<sub>50</sub> values were  $7.92\pm2.71$  nm for the wild-type receptor (n=5),  $361\pm134$  nm for S203A- $\beta_2$ -AR (n=5, P<0.5 vs wild-type receptor),  $1010\pm120$  nm for S204A- $\beta_2$ -AR (n=3, P<0.01 vs wild-type receptor) and  $430\pm90$  nm for S207A- $\beta_2$ -AR (n=4, P<0.05 vs wild-type receptor). These data indicate that Ser<sup>203</sup> plays a role not only in ligand binding but also in receptor activation.

**Discussion** All catecholamine receptors contain two or three serine residues in the fifth transmembrane domain. It has been reported that the serine residues of these receptors that are homologous to  $Ser^{203}$  of  $\beta_2$ -AR play different roles in ligand binding and receptor activation. Rat  $\alpha_{1A}$ -AR has only two serine residues ( $Ser^{188}$  and  $Ser^{192}$ ), which are homologous to  $Ser^{203}$  and  $Ser^{207}$  of human  $\beta_2$ -AR, and they interact with the *meta*- and *para*-hydroxyl groups of adrenaline (Hwa & Perez, 1996). In addition,  $Ser^{188}$  of rat  $\alpha_{1A}$ -AR is essential for receptor activation. Human  $\alpha_{2A}$ -AR also has only two serine residues ( $Ser^{200}$  and  $Ser^{204}$ ), which are homologous to  $Ser^{203}$  and  $Ser^{207}$ 

of human  $\beta_2$ -AR; a mutation of either Ser<sup>200</sup> or Ser<sup>204</sup> decreases both adrenaline binding and the potency with which adrenaline inhibits cyclic AMP generation (Wang *et al.*, 1991). However, Wang *et al.* (1991) suggested that Ser<sup>200</sup> of  $\alpha_{2A}$ -AR does not directly participate in adrenaline binding and receptor activation, because mutation of Ser<sup>200</sup> did not modify the magnitude of inhibition of cyclic AMP generation by adrenaline derivatives with only one hydroxyl group at either the *meta*-position (phenylephrine) or *para*-position (synephrine). These results suggest that the interactions between the hydroxyl groups of adrenaline and the receptor differs between adrenoceptors.

In the present study substitution of an alanine for either  $Ser^{203}$  or  $Ser^{204}$  significantly decreased the affinity of the (–)-isoprenaline derivative with one hydroxyl group at the *meta*-position for  $\beta_2$ -AR, suggesting that the *meta*-hydroxyl group of (–)-isoprenaline interacts with both  $Ser^{203}$  and  $Ser^{204}$ . Our functional analysis of the S203A-, S204A- and S207A- $\beta_2$ -AR mutants indicated that  $Ser^{203}$ , as well as  $Ser^{204}$  and  $Ser^{207}$ , plays an important role not only in ligand binding but also in receptor activation. Cavalli *et al.* (1996) reported that hamster

 $\alpha_{1B}$ -AR has three serine residues in the fifth transmembrane domain, as does human  $\beta_2$ -AR, and proposed that Ser<sup>207</sup> of hamster  $\alpha_{1B}$ -AR fulfils two roles by forming hydrogen bonds: it is a donor for the *meta*-hydroxyl group and is an acceptor for the *para*-hydroxyl group. Therefore, the simplest explanation of our data is that the *meta*-hydroxyl group of (–)-isoprenaline interacts with both Ser<sup>203</sup> and Ser<sup>204</sup> of human  $\beta_2$ -AR in a manner that is similar to the interaction between Ser<sup>207</sup> of hamster  $\alpha_{1B}$ -AR and the *meta*-hydroxyl group.

In conclusion, we have shown that  $Ser^{203}$ , as well as  $Ser^{204}$  and  $Ser^{207}$ , in the fifth transmembrane domain of  $\beta_2$ -AR is involved in ligand binding and receptor activation. However, the precise interactions between each of the serine residues and the hydroxyl groups of (—)-isoprenaline remain to be determined by further analysis of mutant receptors.

We thank Dr R.J. Lefkowitz and Dr S. Nagata for providing pBC- $\beta_2$  and pEF-BOS, respectively.

## References

- CAVALLI, A., FANELLI, F., TADDEI, C., DE BENEDETTI, P.G. & COTECCHIA, S. (1996). Amino acids of the  $\alpha_{1B}$ -adrenergic receptor involved in agonist binding: differences in docking catecholamine to receptor subtypes. *FEBS Lett.*, **399**, 9–13.
- COX, B.A., HENNINGSEN, R.A., SPANOYANNIS, A., NEVE, R.L. & NEVE, K.A. (1992). Contributions of conserved serine residues to the interactions of ligands with dopamine D<sub>2</sub> receptors. *J. Neurochem.*, **59**, 627-635.
- DIXON, R.A.F., SIGAL, I.S., CANDELORE, M.R., REGISTER, R.B., SCATTERGOOD, W., RANDS, E. & STRADER, C.D. (1987). Structural features required for ligand binding to the  $\beta$ -adrenergic receptor. *EMBO J.*, **6**, 3269–3275.
- HWA, J. & PEREZ, D.M. (1996). The unique nature of the serine interactions for  $\alpha_1$ -adrenergic receptor agonist binding and activation. *J. Biol. Chem.*, **271**, 6322–6327.
- KIKKAWA, H., ISOGAYA, M., NAGAO, T. & KUROSE, H. (1997a). The role of the seventh transmembrane region in high affinity binding of a  $\beta_2$ -selective agonist TA-2005. *Mol. Pharmacol.*, **53**, 128 134.
- KIKKAWA, H., KUROSE, H., ISOGAYA, M., SATO, Y. & NAGAO, T. (1997b). Differential contribution of two serine residues of wild type and constitutively active  $\beta_2$ -adrenoceptors to the interaction with  $\beta_2$ -selective agonists. *Br. J. Pharmacol.*, **121**, 1059–1064.

- MIZUSHIMA, S. & NAGATA, S. (1990). pEF-BOS, a powerful mammalian expression vector. *Nuc. Acid Res.*, **18**, 5322.
- POLLOCK, N.J., MANELLI, A.M., HUTCHINS, C.W., STEFFEY, M.E., MACKENZIE, R.G. & FRAIL, D.E. (1992). Serine mutations in transmembrane V of the dopamine D<sub>1</sub> receptor affect ligand interaction and receptor activation. J. Biol. Chem., 267, 17780 – 17786
- STRADER, C.D., CANDELORE, M.R., HILL, W.S., SIGAL, I.S. & DIXON, R.A. (1989). Identification of two serine residues involved in agonist activation of the  $\beta$ -adrenergic receptor. *J. Biol. Chem.*, **264.** 13572 13578.
- STRADER, C.D., SIGAL, I.S., REGISTER, R.B., CANDELORE, M.R., RANDS, E. & DIXON, R.A. (1987). Identification of residues required for ligand binding to the β-adrenergic receptor. *Proc. Natl. Acad. Sci. U.S.A.*, **84**, 4384–4388.
- WANG, C.D., BUCK, M.A. & FRASER, C.M. (1991). Site-directed mutagenesis of  $\alpha_{2A}$ -adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. *Mol. Pharmacol.*, **40**, 168–179.

(Received May 12, 1999 Revised June 22, 1999 Accepted June 30, 1999)